Ignite Creation Date:
2024-05-06 @ 6:48 PM
Last Modification Date:
2024-10-26 @ 2:55 PM
Study NCT ID:
NCT05796206
Status:
RECRUITING
Last Update Posted:
2024-03-13
First Post:
2023-03-08
Brief Title:
A Clinical Study of MIL62 in Systemic Lupus Erythematosus
Sponsor:
Beijing Mabworks Biotech Co Ltd
Organization:
Beijing Mabworks Biotech Co Ltd
Study Overview
Official Title:
A Phase ⅡⅢ Clinical Study to Evaluate the Safety and Efficacy of Recombinant Humanized Monoclonal Antibody MIL62 Injection in the Treatment of Systemic Lupus Erythematosus
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the efficacy safety pharmacokineticsPK pharmacodynamicsPD and ADA of MIL62 compared with placebo in participants with systemic lupus erythematosus
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None